PCSK9抑制剂对代谢相关脂肪肝疾病的影响:简要综述

IF 1.7 Q3 GASTROENTEROLOGY & HEPATOLOGY Przegla̜d Gastroenterologiczny Pub Date : 2023-01-01 DOI:10.5114/pg.2023.126054

Ewelina Jakielska, Paweł Głuszak, Marta Walczak, Wiesław Bryl

{"title":"PCSK9抑制剂对代谢相关脂肪肝疾病的影响:简要综述","authors":"Ewelina Jakielska, Paweł Głuszak, Marta Walczak, Wiesław Bryl","doi":"10.5114/pg.2023.126054","DOIUrl":null,"url":null,"abstract":"Metabolic-associated fatty liver disease (MAFLD), previously known as non-alcoholic fatty liver disease, is a significant epidemiological problem and a well-known cardiovascular risk factor. The increasing number of cases creates the need for new therapeutic methods aimed at improving patient outcomes. Recent studies have highlighted the relationship between MAFLD and proprotein convertase subtilisin/kexin type 9 (PCSK9). Based on the available data, PCSK9 inhibitors appear to have beneficial effects in patients with MAFLD, and they may be a treatment option in the future. Further research is necessary to better evaluate the efficiency of PCSK9 inhibitors in MAFLD treatment.","PeriodicalId":20719,"journal":{"name":"Przegla̜d Gastroenterologiczny","volume":"18 2","pages":"148-153"},"PeriodicalIF":1.7000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/94/ff/PG-18-50394.PMC10395066.pdf","citationCount":"0","resultStr":"{\"title\":\"Effects of PCSK9 inhibitors on metabolic-associated fatty liver disease: a short review.\",\"authors\":\"Ewelina Jakielska, Paweł Głuszak, Marta Walczak, Wiesław Bryl\",\"doi\":\"10.5114/pg.2023.126054\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Metabolic-associated fatty liver disease (MAFLD), previously known as non-alcoholic fatty liver disease, is a significant epidemiological problem and a well-known cardiovascular risk factor. The increasing number of cases creates the need for new therapeutic methods aimed at improving patient outcomes. Recent studies have highlighted the relationship between MAFLD and proprotein convertase subtilisin/kexin type 9 (PCSK9). Based on the available data, PCSK9 inhibitors appear to have beneficial effects in patients with MAFLD, and they may be a treatment option in the future. Further research is necessary to better evaluate the efficiency of PCSK9 inhibitors in MAFLD treatment.\",\"PeriodicalId\":20719,\"journal\":{\"name\":\"Przegla̜d Gastroenterologiczny\",\"volume\":\"18 2\",\"pages\":\"148-153\"},\"PeriodicalIF\":1.7000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/94/ff/PG-18-50394.PMC10395066.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Przegla̜d Gastroenterologiczny\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5114/pg.2023.126054\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Przegla̜d Gastroenterologiczny","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5114/pg.2023.126054","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

代谢性相关脂肪性肝病(MAFLD)，以前被称为非酒精性脂肪性肝病，是一个重要的流行病学问题和众所周知的心血管危险因素。越来越多的病例产生了对旨在改善患者预后的新治疗方法的需求。最近的研究强调了MAFLD与蛋白转化酶枯草素/ keexin 9型(PCSK9)之间的关系。根据现有的数据，PCSK9抑制剂似乎对MAFLD患者有有益的作用，它们可能在未来成为一种治疗选择。为了更好地评估PCSK9抑制剂治疗mald的效果，还需要进一步的研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

摘要图片

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Effects of PCSK9 inhibitors on metabolic-associated fatty liver disease: a short review.

Metabolic-associated fatty liver disease (MAFLD), previously known as non-alcoholic fatty liver disease, is a significant epidemiological problem and a well-known cardiovascular risk factor. The increasing number of cases creates the need for new therapeutic methods aimed at improving patient outcomes. Recent studies have highlighted the relationship between MAFLD and proprotein convertase subtilisin/kexin type 9 (PCSK9). Based on the available data, PCSK9 inhibitors appear to have beneficial effects in patients with MAFLD, and they may be a treatment option in the future. Further research is necessary to better evaluate the efficiency of PCSK9 inhibitors in MAFLD treatment.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Przegla̜d Gastroenterologiczny GASTROENTEROLOGY & HEPATOLOGY-

CiteScore

2.20

自引率

7.70%

发文量

审稿时长

6-12 weeks

期刊介绍： Gastroenterology Review is a journal published each 2 months, aimed at gastroenterologists and general practitioners. Published under the patronage of Consultant in Gastroenterology and Polish Pancreatic Club.